AKN-028 is an orally active and potent FLT3 tyrosine kinase inhibitor (IC50 = 6 nM). AKN-028 causes dose-dependent inhibition of FLT3 autophosphorylation.

Product information

CAS Number: 1175017-90-9

Molecular Weight: 302.33

Formula: C17H14N6

Chemical Name: N2-(1H-indol-5-yl)-6-(pyridin-4-yl)pyrazine-2,3-diamine

Smiles: NC1=NC=C(N=C1NC1C=C2C=CNC2=CC=1)C1C=CN=CC=1

InChiKey: JLRIJKVMMZEKDF-UHFFFAOYSA-N

InChi: InChI=1S/C17H14N6/c18-16-17(22-13-1-2-14-12(9-13)5-8-20-14)23-15(10-21-16)11-3-6-19-7-4-11/h1-10,20H,(H2,18,21)(H,22,23)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

AKN-028 triggers apoptosis in MV4-11 by activation of caspase 3. AKN-028 (10 μM) is cytotoxic to AML cell lines and induces apoptosis in the AML cell line MV4-11.

In Vivo:

AKN-028 (15 mg/kg, Subcutaneously injection twice daily) exhibits anti-tumor activities for acute myeloid leukemia (AML) models.

Products are for research use only. Not for human use.